aTyr Restructures, Cuts 30% of Workforce to Extend Cash Runway to 2028
ATYR sits 29% above its 52-week low of $0.395 on light trading volume (0.1× avg).
Summary
aTyr Pharma is slashing its workforce by approximately 60% and prioritizing its lead drug efzofitimod for interstitial lung disease (ILD). The restructuring is expected to save approximately $13 million annually beginning Q4 2026, extending the cash runway into the second half of 2028. This follows the recent termination of the Kyorin partnership, which returned full global rights to efzofitimod but also eliminated $155 million in potential milestones. The move signals a leaner, more focused operation ahead of the new Phase 3 trial for pulmonary sarcoidosis. With a market cap around $50 million and shares near $0.51, the extended runway reduces near-term dilution risk and strengthens the company's negotiating position. CFO Jill Broadfoot and General Counsel Nancy Denyes step down September 30, 2026; Brandon Yaras becomes CFO October 1.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Workforce reduction is approximately 60%, not 30%. CFO Jill Broadfoot and General Counsel Nancy Denyes step down September 30, 2026; Brandon Yaras becomes CFO October 1. Annualized savings expected to be approximately $13 million, beginning Q4 2026.
At the time of this announcement, ATYR was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.1M. The 52-week trading range was $0.40 to $6.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.